Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05873907 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AMG 592 in Healthy Participants
A Phase 1 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
NCT05873907 is a Phase 1 study that has completed, run by Amgen. The registered enrollment target is 64 participants.
The verdict
NCT05873907, a Phase 1 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the safety, tolerability and immunogenicity profile of single and multiple dose administrations of AMG 592 in healthy participants.
Interventions
- OTHER Placebo
- DRUG AMG 592
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2015-10-19 |
| Est. Completion | 2017-07-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05873907
The ClinicalTrials.gov registry entry for NCT05873907 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05873907 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05873907 about?
NCT05873907 is a clinical study titled "A Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AMG 592 in Healthy Participants". The primary objective of this study is to evaluate the safety, tolerability and immunogenicity profile of single and multiple dose administrations of AMG 592 in healthy participants.
What is the current status of trial NCT05873907?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2015-10-19. Estimated completion is 2017-07-28.
What interventions are being tested in trial NCT05873907?
The interventions under investigation include: Placebo (OTHER), AMG 592 (DRUG).
Who is sponsoring clinical trial NCT05873907?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.